Marion Biotech: Uzbekistan links child deaths to India cough syrup
Uzbekistan's health ministry has said that 18 children have died after drinking a cough syrup manufactured by Indian drug maker Marion Biotech.
ministry said that preliminary tests showed a batch of the medicine contained ethylene glycol, a toxic substance.
ren were given the Dok-1 Max syrup without a doctor's prescription, it said.
mount they consumed also exceeded the standard dose for children.
gation from Uzbekistan comes weeks after The Gambia also linked child deaths to cough syrups made by another Indian firm. 
India's health ministry said in a statement that its officials have been "in regular contact with the national drug regulator of Uzbekistan regarding the matter" since 27 December.
It added that health officials have conducted an inspection of Marion Biotech's facility in Noida in Uttar Pradesh state.
"The samples of the cough syrup have been taken from the manufacturing premises and sent to Regional Drugs Testing Laboratory, Chandigarh for testing," the statement added.
Marion Biotech has not responded to the BBC's request for comment yet.
News agency ANI has quoted a Marion Biotech executive as saying that the company has halted production of the syrup temporarily. He added that the government was conducting an enquiry and that the firm would take action accordingly.
Marion Biotech is based in Noida, near India's national capital Delhi. Its website is currently down, but the company's LinkedIn page says it was founded in 1999 and that its products are "household names in Central Asian countries, Central and Latin America, South East Asia and Africa".
India produces a third of the world's medicines, mostly in the form of generic drugs.
untry, home to some of the fastest-growing pharmaceutical companies, is known as the "world's pharmacy" and meets much of the medical needs of developing countries.
Uzbek ministry statement, dated 27 December, says that Dok-1 Max tablets and syrup have been sold in the country since 2012. 
"It was found that the deceased children, before admission to hospital treatment, took this drug at home for 2-7 days, 3-4 times a day, 2.5-5ml, which exceeds the standard dose of the drug for children," the ministry said.
ment did not specify over what time period the deaths occurred. BBC Monitoring had reported on 23 December, citing news website Gazeta.uz, that Uzbek authorities were investigating "claims that 15 children died in central Samarkand region over the past two months after taking a cough syrup made in India".
On 26 December, Podrobno.uz news website reported that 21 children - 15 of them under the age of three - were treated for acute kidney failure "allegedly caused by the India-made cough syrup Dok-1 Max between September and December". Three of the patients recovered.
ministry also said that "preliminary laboratory studies have shown that this series of Dok-1 Max syrup contains ethylene glycol".
In October, the World Health Organization (WHO) had sounded a global alert and linked four India-made cough syrups to the deaths of 66 children from kidney injuries in The Gambia. It said tests on samples of the syrup showed that they contained unacceptable amounts of toxic substances diethylene glycol and ethylene glycol.
Both the Indian government and the company, Maiden Pharmaceuticals, have denied the allegations.
India said earlier in December that tests on the four syrups showed that they complied with specifications, and a government official told the BBC that the WHO had been "presumptuous" in blaming the syrups. But the WHO said it stood by the action taken.
Last week, a parliamentary committee in The Gambia recommended prosecution of Maiden Pharmaceuticals after weeks of investigation. The committee also recommended banning all products by the firm in the country.
As with the tragic reports from Uzbekistan, deaths of children in The Gambia were linked to Indian-made cough mixtures laced with high quantities of ethylene glycol or diethylene glycol - both toxic substances with the former found in, among other things, anti-freeze. 
Indian laws do require that all manufacturers adhere to strict quality control and production practices.
Experts we spoke to said that regulations suggest drugs meant for export are subject to same standards as those meant for local consumption, but it is unclear exactly how those standards are enforced. 
Public-health activist Dinesh Thakur points out the lack of proper accountability for producing sub-standard medicine. Currently, a fine of $242 (£220) and a possible prison sentence of up to two years is the punishment.
"Unless one can causally establish a direct link between a sub-standard drug and a fatality, this is the norm of punishment meted out," he told the BBC.
Countries such as Vietnam and Indonesia have banned Indian-made manufacturers due to substandard medicines in the past. The US Food and Drugs Administration has also banned some Indian-made medicines due to quality control issues. 